Roche read­ies a hunt for mar­ket­ing OK on he­mo­phil­ia block­buster hope­ful emi­cizum­ab af­ter PhI­II suc­cess

The next big thing on Roche’s list of would-be block­busters—the he­mo­phil­ia A drug emi­cizum­ab (or ACE910)—came through in a Phase III study, set­ting up a quick lob to reg­u­la­tors around the world.

Long one of Roche’s top prospects, as laid out by phar­ma chief Daniel O’Day, Genen­tech re­searchers say that the drug hit the pri­ma­ry as well as all the sec­ondary end­points in their late-stage test. The big goal was a sta­tis­ti­cal­ly sig­nif­i­cant drop in the num­ber of bleeds among pa­tients with in­hibitors to fac­tor VI­II. And one of the sec­on­daries was a re­duc­tion in bleeds record­ed in an “in­tra-pa­tient com­par­i­son in peo­ple who had re­ceived pri­or by­pass­ing agent pro­phy­lax­is treat­ment.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.